Despite the shortcomings of current therapies—which are only
moderately effective and often impose a high side-effect burden—the market for
overactive bladder (OAB) drugs has grown significantly and steadily over the
last ten or more years. As a result, it is an attractive environment for drug
companies, who persevere in the face of recent OAB clinical failures to develop
novel therapies that capitalize on physicians’ eagerness for more-effective
drugs with novel mechanisms of action.
Questions Answered in This Report:
Thought-leading physicians contend that although OAB is
increasingly common with age, a large percentage of those suffering from it are
unrecognized and untreated. How will the aging of the populations in the
major pharmaceutical markets affect the size of the OAB prevalent population?
Which factors impede the identification and treatment of OAB patients? What
trends in diagnosis and drug-treatment rates are predicted through 2019?
In their ongoing efforts to establish positions in the OAB
market, drug developers have focused on solving two major unmet needs:
achieving greater control of symptoms compared with oral anticholinergics and
optimizing tolerability to improve compliance. How have the launches of
several new anticholinergic brands affected the distribution of major-market
sales for agents in this class? How do products’ efficacy and tolerability
drive prescribing decisions? Is any anticholinergic poised to unseat ER
tolterodine (Pfizer/Almirall’s Detrol-LA/Detrusitol-XL) as the top-selling
agent in this class?
Thought-leading physicians tell us they are eager for novel OAB
therapies with mechanisms of action that differ from anticholinergics. Which
novel noncholinergic agents are expected to launch during the 2009-2019
forecast period? Will these therapies displace or be synergistic with
anticholinergics in the OAB treatment algorithm?
Generic erosion is a significant constraint on the future
growth of the OAB market. Which products are expected to lose market
exclusivity by 2019? How will expensive branded agents fare in the face of
generic entrants and biosimilar competitors?
Markets: United States, France, Germany,
Italy, Spain, United Kingdom, Japan.
Primary research: 22 country-specific interviews with
urologists, urogynecologists, and GP/PCPs.
Epidemiology: Total prevalent cases of OAB; prevalent
cases of OAB by symptom, including urinary incontinence, urinary frequency, and
Emerging therapies: Phase II: eight drugs; Phase III:
two drugs; preregistration: one drug. Coverage of select preclinical and Phase
Market forecast features: Using a proprietary analogue
generic erosion model and anticipated launch dates based on primary and
secondary research, we forecast drug sales for the treatment of OAB through